B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
+20.95%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.1B
AUM Growth
+$3.1B
(+14%)
Cap. Flow
+$365M
Cap. Flow
% of AUM
11.77%
Top 10 Holdings %
Top 10 Hldgs %
37.76%
Holding
89
New
16
Increased
13
Reduced
14
Closed
12
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$77.2M |
| 2 |
Viking Therapeutics
VKTX
|
$58.5M |
| 3 |
CG Oncology
CGON
|
$49.6M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$45.1M |
| 5 |
Intuitive Surgical
ISRG
|
$40.1M |
Top Sells
| 1 |
Immunocore
IMCR
|
$41.8M |
| 2 |
Day One Biopharmaceuticals
DAWN
|
$33.7M |
| 3 |
Lantheus
LNTH
|
$30.7M |
| 4 |
Keros Therapeutics
KROS
|
$25.3M |
| 5 |
Harrow
HROW
|
$18.2M |
Sector Composition
| 1 | Healthcare | 57.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $27.5M | 0.89% | +1,392,716 | New | +$27.5M |
|
27
Thermo Fisher Scientific
TMO
$186B
| $27.4M | 0.88% | 47,149 -28,600 | -38% | -$16.6M |
|
28
Repligen
RGEN
$6.88B
| $26.3M | 0.85% | 142,836 +40,138 | +39% | +$7.38M |
|
|
NVRO
29
DELISTED
NEVRO CORP.
NVRO
| $25.7M | 0.83% | 1,776,368 | – | – |
|
30
Inspire Medical Systems
INSP
$2.77B
| $21.8M | 0.7% | 101,492 -83,166 | -45% | -$17.9M |
|
31
Cullinan Oncology
CGEM
$445M
| $21.1M | 0.68% | 1,240,865 | – | – |
|
32
Tourmaline Bio
TRML
$601M
| $20.8M | 0.67% | 906,820 | – | – |
|
33
Lexeo Therapeutics
LXEO
$259M
| $20.7M | 0.67% | +1,322,277 | New | +$20.7M |
|
34
Spyre Therapeutics
SYRE
$996M
| $19.5M | 0.63% | 515,000 | – | – |
|
35
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.1M | 0.62% | +218,896 | New | +$19.1M |
|
36
Structure Therapeutics
GPCR
$1.11B
| $18.7M | 0.6% | 435,823 +155,665 | +56% | +$6.67M |
|
37
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.2M | 0.55% | 3,379,577 -2,338,900 | -41% | -$11.9M |
|
38
iTeos Therapeutics
ITOS
| $15.9M | 0.51% | +1,162,374 | New | +$15.9M |
|
39
Mineralys Therapeutics
MLYS
$1.03B
| $14.8M | 0.48% | 1,147,154 -876,746 | -43% | -$11.3M |
|
40
Alector
ALEC
$238M
| $14.3M | 0.46% | 2,380,704 -943,604 | -28% | -$5.68M |
|
41
Arcutis Biotherapeutics
ARQT
$1.86B
| $12.9M | 0.42% | +1,300,000 | New | +$12.9M |
|
|
ELEV
42
DELISTED
Elevation Oncology
ELEV
| $12.2M | 0.39% | +2,377,647 | New | +$12.2M |
|
43
BridgeBio Pharma
BBIO
$9.89B
| $10.7M | 0.34% | +344,827 | New | +$10.7M |
|
44
Iovance Biotherapeutics
IOVA
$807M
| $9.78M | 0.32% | +660,022 | New | +$9.78M |
|
|
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.59M | 0.31% | 609,643 -559,847 | -48% | -$8.81M |
|
46
Olema Pharmaceuticals
OLMA
$375M
| $7.97M | 0.26% | +704,344 | New | +$7.97M |
|
47
Pulmonx
LUNG
$69.7M
| $6.98M | 0.22% | 752,541 -35,413 | -4% | -$328K |
|
|
DBVT
48
DBV Technologies
DBVT
$264M
| $5.93M | 0.19% | 7,843,285 | – | – |
|
49
Outset Medical
OM
$247M
| $5.33M | 0.17% | 2,400,427 | – | – |
|
50
Adaptive Biotechnologies
ADPT
$2.01B
| $4.36M | 0.14% | 1,357,490 | – | – |
|